GoAI
Get started
enGene Holdings Inc. logo

enGene Holdings Inc.

ENGN

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.78

+$0.01 · +0.56%

Aug 21, 4:00 PM ET

ENGN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

19

Strong Down

Sentiment

56

Mixed

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
Ronald H. W. Cooper
Listed since
Feb 1, 2022
Employees
82

Market position

Day range

Current $1.78

52-week range

Current $1.78

Open
$1.785
Previous close
$1.77
Volume
242.73K
0.16× average
Average volume
1.49M
Average daily volume
Market cap
119.24M USD
Beta
-0.28
Market reference 1
50-day average
$1.7905
-0.59% below average
200-day average
$5.9127
-69.90% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
350.21M USD
P/E (TTM)
-1.35×
P/B (TTM)
0.49×
P/S (TTM)
0×
EV / EBITDA
-3.08×
Earnings yield
-31.83%
Free cash flow yield
-27.33%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-69.94%
Return on assets
-52.97%
Return on invested capital
-61.74%

Financial health

Debt / equity
0.13×
Current ratio
6.3×
Altman Z-score
-0.99
Piotroski F-score
0 of 9

Financial statements

Income trends

Operating income

−123.17M USD-97.71%

Net income

−117.3M USD-112.73%
Income trends across reported periods−5.14M USD−48.06M USD−90.98M USD−133.89M USDOperating income, FY2021: −15.87M USDOperating income, FY2022: −19.43M USDOperating income, FY2023: −26.06M USDOperating income, FY2024: −62.3M USDOperating income, FY2025: −123.17M USDNet income, FY2021: −23.44M USDNet income, FY2022: −24.46M USDNet income, FY2023: −99.92M USDNet income, FY2024: −55.14M USDNet income, FY2025: −117.3M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −15.87M USD. Operating income FY2022 −19.43M USD. Operating income FY2023 −26.06M USD. Operating income FY2024 −62.3M USD. Operating income FY2025 −123.17M USD. Net income FY2021 −23.44M USD. Net income FY2022 −24.46M USD. Net income FY2023 −99.92M USD. Net income FY2024 −55.14M USD. Net income FY2025 −117.3M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development94.48M USD38.32M USD16.46M USD15.47M USD12.46M USD
Selling, general, and administrative28.69M USD23.98M USD8.47M USD3.26M USD3.16M USD
Operating expenses123.17M USD62.3M USD26.06M USD19.43M USD15.87M USD
Interest income9.43M USD10.41M USD1.12M USD129K USD25K USD
Interest expense2.99M USD2.8M USD4.95M USD1.42M USD5.02M USD
Depreciation and amortization509K USD323K USD175K USD238K USD272K USD
Operating income−123.17M USD−62.3M USD−26.06M USD−19.43M USD−15.87M USD
Net income−117.3M USD−55.14M USD−99.92M USD−24.46M USD−23.44M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
40%
4 beats, 6 misses, 0 met estimates
Average EPS surprise
-7.57%
10 comparable reports
Latest EPS result
-0.43
Estimate -0.48 · Beat by 10.42%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.3-0.46-0.61-0.77Q4 '24BeatQ1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Dec 19, 2024: actual -0.34, estimate -0.396, surprise +14.08%, Beat. Q1 2025, reported Mar 10, 2025: actual -0.48, estimate -0.368, surprise -30.51%, Miss. Q2 2025, reported Jun 12, 2025: actual -0.51, estimate -0.497, surprise -2.56%, Miss. Q3 2025, reported Sep 11, 2025: actual -0.57, estimate -0.498, surprise -14.46%, Miss. Q4 2025, reported Dec 22, 2025: actual -0.73, estimate -0.567, surprise -28.77%, Miss. Q1 2026, reported Mar 9, 2026: actual -0.44, estimate -0.55, surprise +20.00%, Beat. Q2 2026, reported Jun 15, 2026: actual -0.43, estimate -0.48, surprise +10.42%, Beat. Q3 2026, reported Sep 14, 2026: actual —, estimate -0.47, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.00

68.54% upside
Past 12 months12-month forecastHigh $4.00Average $3.00Low $2.00

Corporate actions

Corporate action history

Dividend

Ex-dividend Feb 2, 2015

$0.13

Quarterly

Dividend

Ex-dividend Dec 1, 2014

$0.14

Monthly

Payment Dec 5, 2014

Dividend

Ex-dividend Nov 3, 2014

$0.15

Monthly

Payment Nov 7, 2014

Dividend

Ex-dividend Oct 1, 2014

$0.15

Semi-Annual

Payment Oct 7, 2014

Dividend

Ex-dividend May 1, 2014

$0.13

Semi-Annual

Dividend

Ex-dividend Dec 2, 2013

$0.12

Monthly

Payment Dec 6, 2013

ENGN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ENGN

research.disclaimer